Luigi Manenti

Outlook Microsoft Office 365 Google Font API WordPress.org Mobile Friendly Basis Circle

claudin1 cldn1 claudin oncology cancer kidney fibrosis rare diseases nephrology lung fibrosis liver fibrosis alef02 drug development drug discovery pulmonology hepatology fibrosis antibodydrug conjugates adc hnscc idiopathic pulmonary fibrosis ancaassociated vasculitis alep02 alep03 lixudebart pharmaceutical manufacturing claudin-1 monoclonal antibodies antibody-drug conjugates adcs solid tumors cancer therapy r&d pipeline clinical development tumor targeting immune checkpoint blockade first-in-class biotechnology fda fast track designation human clinical trials jacques lacan's constructs cancer immunotherapy therapeutic target exposed claudin-1 tumor microenvironment extracellular matrix remodeling pharmaceutical development oncology drug development fibrotic signaling renal diseases preclinical programs t-cell engagers anticancer antibody biologic drugs pharmaceutical pipelines personalized medicine cancer biomarkers tumor microenvironment studies biopharma clinical-stage biotech targeted therapies neoplastic diseases research & development fdaind clearance lean development biotherapeutics cancer care clinical trials industries pipeline phase 1/2 trials clinical candidate anti-claudin-1 therapies cancer treatment fibrosis reversal squamous cancers organ fibrosis clinical-stage biotechnology innovative biopharmaceuticals precision medicine unmet medical needs patient populations advanced liver fibrosis anca-associated vasculitis therapeutic potential biotechnology industry pharmaceutical industry fibrotic diseases proprietary technology platform first-in-class therapies clinical operations basel switzerland patient demographics healthcare providers clinical trial participants partnerships funding series d financing competitive landscape hospital & health care pharmaceuticals medical health care health wellness & fitness